Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Core Viewpoint - Theralase® Technologies Inc. has initiated a non-brokered private placement to raise up to $CAN 2,000,000 for advancing its clinical studies and working capital needs [1][3]. Group 1: Offering Details - The private placement consists of units priced at $CAN 0.17, each unit includes one common share and one warrant [2]. - Each warrant allows the holder to purchase one common share at an exercise price of $CAN 0.21 for 60 months following the closing date [2]. - The offering is expected to close around the week of December 15, 2025, pending necessary approvals [4]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized to further the Phase II Non-Muscle Invasive Bladder Cancer clinical study and for general working capital [3]. Group 3: Regulatory and Compliance - The offering is available to accredited investors in Canada and U.S. persons under specific exemptions from registration requirements [5]. - All securities issued will be subject to a hold period of four months and one day from the closing date [3]. Group 4: Finder's Fees - The company will pay a finder's fee of 7% of gross proceeds and issue non-transferable finder warrants equal to 7% of the total units issued [6]. Group 5: Company Overview - Theralase® is a clinical stage pharmaceutical company focused on developing light, radiation, sound, and drug-activated therapeutics for treating cancer, bacteria, and viruses [9].